Integra Lifesciences Holdings (IART) Equity Average (2010 - 2026)

Integra Lifesciences Holdings' Equity Average history runs 17 years deep, the most recent figure standing at $1.0 billion for Q1 2026.

• In Q1 2026, Equity Average fell 32.04% year-over-year to $1.0 billion; the TTM figure through Mar 2026 stood at $1.0 billion (down 32.04% YoY), while the FY2025 annual figure was $1.3 billion, down 17.38% from the prior year.
• Equity Average came in at $1.0 billion for Q1 2026 at Integra Lifesciences Holdings, roughly flat from $1.0 billion in the prior quarter.
• In the past five years, Equity Average ranged from a high of $1.8 billion in Q4 2022 to a low of $1.0 billion in Q3 2025.
• A 5-year average of $1.5 billion and a median of $1.6 billion in 2023 frame the typical range for Equity Average.
• Across the five-year window, Equity Average gained 8.4% in 2022 and plunged 32.14% in 2025, its largest moves.
• Integra Lifesciences Holdings' Equity Average stood at $1.8 billion in 2022, then decreased by 10.25% to $1.6 billion in 2023, then declined by 3.16% to $1.5 billion in 2024, then slumped by 32.14% to $1.0 billion in 2025, then gained by 0.23% to $1.0 billion in 2026.
• According to Business Quant data, Equity Average over the past three periods registered $1.0 billion, $1.0 billion, and $1.0 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison